• 出版社/出版日：360iResearch / 2022年10月11日
|Single User（1名利用、印刷可）||￥643,370 (USD4,949)||▷ お問い合わせ|
|Enterprise License（企業利用、印刷可）||￥1,293,370 (USD9,949)||▷ お問い合わせ|
|360iResearch社の当調査資料によると、2021年に5,921.89百万ドルであった世界の気管支炎治療市場規模は2022年に6,305.21百万ドルとなり、2027年までに年平均6.64％成長して8,714.13百万ドルまで拡大すると見込まれています。当書は、気管支炎治療の世界市場を対象とした調査・分析結果をまとめたものであり、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別分析（急性気管支炎、慢性気管支炎）、治療別分析（薬物療法、酸素療法）、薬剤分類別分析（抗炎症薬、抗生物質、気管支拡張薬、その他）、エンドユーザー別分析（クリニック、病院薬局、小売薬局）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの内容を掲載しています。なお、当書内の企業情報としては、American Well Corporation、AstraZeneca PLC、Boehringer Ingelheim International GmbH、Cigna Corporation、Dr. Reddy’s Laboratories Ltd、F. Hoffmann-La Roche Ltd.、GlaxoSmithKline Pharmaceuticals Limited、Johnson & Johnson Services, Incなどが含まれています。|
The Global Bronchitis Treatment Market size was estimated at USD 5,921.89 million in 2021 and expected to reach USD 6,305.21 million in 2022, and is projected to grow at a CAGR 6.64% to reach USD 8,714.13 million by 2027.
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Bronchitis Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across Acute Bronchitis and Chronic Bronchitis.
Based on Treatment, the market was studied across Drugs and Oxygen Therapy.
Based on Class of Drugs, the market was studied across Anti-inflammatory Drugs, Antibiotics, Bronchodilator, and Others.
Based on End User, the market was studied across Clinics, Hospital Pharmacies, Others, and Retail Pharmacies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Bronchitis Treatment market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Bronchitis Treatment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Bronchitis Treatment Market, including American Well Corporation, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Cigna Corporation, Dr. Reddy’s Laboratories Ltd, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Pharmaceuticals Limited, Johnson & Johnson Services, Inc, Mayo Foundation for Medical Education and Research (MFMER), Melinta Therapeutics, Inc., Novartis International AG, Pfizer Inc., Reckitt Benckiser Group PLC, Sanofi S.A, and TelaCare Health Solutions, LLC.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Bronchitis Treatment Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Bronchitis Treatment Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Bronchitis Treatment Market?
4. What is the competitive strategic window for opportunities in the Global Bronchitis Treatment Market?
5. What are the technology trends and regulatory frameworks in the Global Bronchitis Treatment Market?
6. What is the market share of the leading vendors in the Global Bronchitis Treatment Market?
7. What modes and strategic moves are considered suitable for entering the Global Bronchitis Treatment Market?
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
188.8.131.52. Increase in geriatric population with surge in incidence of bronchitis
184.108.40.206. High population with smoking habits and increasing levels of pollutants
220.127.116.11. Rising prevalence of COPD patients
18.104.22.168. Patent expiry of drugs
22.214.171.124. Advances in the COPD therapies such as combination therapies and small cell therapy
126.96.36.199. Collaborative initiatives with government for treatment awareness and market penetration in developing economies
188.8.131.52. Risk and side effects associated with oxygen therapy
5.2. Cumulative Impact of COVID-19
6. Bronchitis Treatment Market, by Type
6.2. Acute Bronchitis
6.3. Chronic Bronchitis
7. Bronchitis Treatment Market, by Treatment
7.3. Oxygen Therapy
8. Bronchitis Treatment Market, by Class of Drugs
8.2. Anti-inflammatory Drugs
9. Bronchitis Treatment Market, by End User
9.3. Hospital Pharmacies
9.5. Retail Pharmacies
10. Americas Bronchitis Treatment Market
10.6. United States
11. Asia-Pacific Bronchitis Treatment Market
11.10. South Korea
12. Europe, Middle East & Africa Bronchitis Treatment Market
12.15. Saudi Arabia
12.16. South Africa
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. American Well Corporation
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. AstraZeneca PLC
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Boehringer Ingelheim International GmbH
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Cigna Corporation
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Dr. Reddy’s Laboratories Ltd
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. F. Hoffmann-La Roche Ltd.
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. GlaxoSmithKline Pharmaceuticals Limited
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Johnson & Johnson Services, Inc
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Mayo Foundation for Medical Education and Research (MFMER)
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Melinta Therapeutics, Inc.
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Novartis International AG
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Pfizer Inc.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Reckitt Benckiser Group PLC
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Sanofi S.A
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. TelaCare Health Solutions, LLC
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
15.1. Discussion Guide
15.2. License & Pricing